-
公开(公告)号：US20230398214A1
公开(公告)日：2023-12-14
申请号：US17633294
申请日：2020-08-06
发明人： Yair REISNER , Esther BACHAR-LUSTIG , Assaf LASK , Noga OR-GEVA , Rotem GIDRON BUDOVSKY , Rakefet SIDLIK MUSKATEL
IPC分类号： A61K39/00 , C12N5/0783 , A61K31/664 , A61P37/06
CPC分类号： A61K39/4622 , C12N5/0636 , A61K39/4633 , A61K39/4614 , A61K39/464411 , A61K39/46444 , A61K39/464838 , A61K31/664 , A61P37/06 , A61K39/464429 , A61K39/4621 , C12N2501/2307 , C12N2501/2315 , C12N2501/2321 , C12N2502/1121
摘要： Methods of generating an isolated population of non-graft versus host disease (GVHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, are disclosed. Cells generated by the methods, pharmaceutical compositions and methods of treatment are also disclosed.
-
2.发明公开公开(公告)号：US20230190799A1
公开(公告)日：2023-06-22
申请号：US17870024
申请日：2022-07-21
申请人： City of Hope
发明人： John E. Shively , Maciej Kujawski , Seung E. Cha , Paul Yazaki
IPC分类号： A61K35/17 , C07K16/30 , A61K31/664 , A61P35/00 , A61P1/00 , A61K38/20 , A61K38/17 , A61K39/395
CPC分类号： A61K35/17 , C07K16/3007 , A61K31/664 , A61P35/00 , A61P1/00 , A61K38/2013 , A61K38/1774 , A61K39/39558 , C07K2317/622 , C07K2317/55 , A61K2039/545
摘要： Aspects of the present disclosure provide methods for treating a subject having a carcinoembryonic antigen (CEA)-positive tumor using a conditioning regimen (lymphodepleting treatment), which comprises administering one or more doses of a lymphodepleting agent to a subject, and a treatment regimen, which comprises administrating one or more doses of the anti-CEA CAR T cells and/or the ICK proteins to the subject.
-
公开(公告)号：US11666631B2
公开(公告)日：2023-06-06
申请号：US16504909
申请日：2019-07-08
发明人： Stephen Mark Robbins , Donna Lorraine Senger , Jennifer Joy Rahn , Arthur Wing Sze Lau , Daniel Abraham Muruve , Saurav Roy Choudhury , Liane Babes , Paul Kubes
IPC分类号： A61K38/17 , A61P43/00 , A61P37/06 , A61P13/12 , A61P29/00 , A61P35/04 , A61K9/00 , A61K31/662 , A61K31/664 , A61K38/08 , A61K38/10 , A61K38/55 , C07C323/58 , C07F9/30 , C07K16/40 , C12N9/48
CPC分类号： A61K38/1709 , A61K9/0019 , A61K31/662 , A61K31/664 , A61K38/08 , A61K38/10 , A61K38/55 , A61P13/12 , A61P29/00 , A61P35/04 , A61P37/06 , A61P43/00 , C07C323/58 , C07F9/302 , C07K16/40 , C12N9/485 , C12Y304/13019 , C07K2317/76
摘要： Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
-
4.发明申请公开(公告)号：US20190216783A1
公开(公告)日：2019-07-18
申请号：US16295644
申请日：2019-03-07
申请人： AbbVie Inc.
发明人： Gary Gordon
IPC分类号： A61K31/4184 , A61K31/4164 , A61K31/41 , A61K31/704 , A61K31/282 , A61K31/337 , A61K31/664
CPC分类号： A61K31/4184 , A61K31/282 , A61K31/337 , A61K31/41 , A61K31/4164 , A61K31/664 , A61K31/704
摘要： The invention relates to a method for the treatment of triple negative breast cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, and an effective amount of carboplatin, in combination with standard of care.
-
公开(公告)号：US20180200231A1
公开(公告)日：2018-07-19
申请号：US15743721
申请日：2016-07-12
发明人： Marcello ALLEGRETTI , Andrea ARAMINI , Maria Candida CESTA , Gianluca BIANCHINI , Laura BRANDOLINI , Patrizia ANGELICO
IPC分类号： A61K31/426 , A61K45/06 , A61K31/165 , A61K31/664 , A61P13/10
CPC分类号： A61K31/426 , A61K31/165 , A61K31/381 , A61K31/407 , A61K31/664 , A61K31/675 , A61K31/704 , A61K45/06 , A61K2300/00 , A61P13/10
摘要： The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB), also including IC/PBS and/or OAB induced by anticancer therapy. Methods of treatment and/or prevention, combinations and kits comprising said IL-8 inhibitors are also covered therein.
-
公开(公告)号：US09919060B2
公开(公告)日：2018-03-20
申请号：US15425758
申请日：2017-02-06
发明人： Steven Albert Everett , Saraj Ulhaq
IPC分类号： A61K47/48 , A61K31/37 , A61K31/52 , A61K31/343 , A61K31/381 , A61K31/428 , A61K31/513 , A61K31/665 , A61K47/54 , C07D491/22 , C07D487/04 , C07D417/12 , C07D409/12 , C07D407/12 , C07D405/14 , C07D405/12 , C07D405/04 , C07D311/18 , C07D311/16 , C07D307/80 , A61K31/664 , A61K31/4184 , A61K31/352
CPC分类号： A61K47/545 , A61K31/343 , A61K31/352 , A61K31/37 , A61K31/381 , A61K31/4184 , A61K31/428 , A61K31/513 , A61K31/52 , A61K31/664 , A61K31/665 , C07D307/80 , C07D311/16 , C07D311/18 , C07D405/04 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D417/12 , C07D487/04 , C07D491/22
摘要： The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.
-
公开(公告)号：US09789173B2
公开(公告)日：2017-10-17
申请号：US14295660
申请日：2014-06-04
发明人： John W. Hadden
IPC分类号： A61K39/00 , A61K38/21 , A61K31/405 , A61K31/664 , A61K38/20 , A61K38/19 , A61K39/39 , A61K31/675 , A61K31/496 , A61K31/5383 , A61K45/06
CPC分类号： A61K39/0011 , A61K31/405 , A61K31/496 , A61K31/5383 , A61K31/664 , A61K31/675 , A61K38/191 , A61K38/193 , A61K38/20 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/2086 , A61K38/21 , A61K38/217 , A61K39/39 , A61K45/06 , A61K2039/5154 , A61K2039/5158 , A61K2039/55522 , A61K2300/00
摘要： A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.
-
公开(公告)号：US20170232015A1
公开(公告)日：2017-08-17
申请号：US15581134
申请日：2017-04-28
IPC分类号： A61K31/664 , A61K47/20 , A61K47/12 , A61K47/10 , A61K9/08
CPC分类号： A61K31/664 , A61K9/0019 , A61K9/08 , A61K31/675 , A61K47/10 , A61K47/12 , A61K47/20
摘要： Cyclophosphamide containing compositions preferably in the form of solutions having extended stability are disclosed. The compositions contain cyclophosphamide, ethanol and an ethanol soluble acidifying agent such as citric acid. Ready to dilute or ready to use cyclophosphamide containing compositions of the invention maintain high levels cyclophosphamide content after about 18 or 24 months at a temperature of about 5° C.
-
公开(公告)号：US20170143744A1
公开(公告)日：2017-05-25
申请号：US15402712
申请日：2017-01-10
发明人： Riyaz Ahmed SHAIK , Ananya SAHA , Svb Janardhan GARIKIPATI , Akash CHAURASIYA , Bhavesh Vallabhbhai PATEL , Harshal BHAGWATWAR , Ashok Pillai SUMITRA
CPC分类号： A61K31/664 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/675 , A61K47/10 , A61K47/26 , A61K47/44 , B01D15/08
摘要： The present invention relates to stable liquid pharmaceutical formulations of cyclophosphamide comprising cyclophosphamide and at least one pharmaceutically acceptable excipient wherein moisture content of the liquid formulation is less than about 2.0% by weight. The invention further relates to stable liquid formulations of cyclophosphamide prepared by a process comprising a step of reducing the moisture content from cyclophosphamide or liquid compositions of cyclophosphamide or both. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration either as ready-to-use or ready-to-dilute for treating various cancer disorders.
-
公开(公告)号：US20170115278A1
公开(公告)日：2017-04-27
申请号：US15356243
申请日：2016-11-18
申请人： Yong Chi Lin , Po Wen Lin , Po Yu Lin , Amy Huimeei Lo , Jing Meei Lin
发明人： Yong Chi Lin , Po Wen Lin , Po Yu Lin , Amy Huimeei Lo , Jing Meei Lin
IPC分类号： G01N33/50 , A61K31/664
CPC分类号： G01N33/5055 , A61K31/664 , A61K36/73 , G01N33/5094
摘要： A useful HIV remedy process consists of 4 elements: guinea pig or mouse peritoneal derived adherent macrophages/monocytes as effector cells; cyclophosphamide as an immuno suppressor; chicken RBC as target cells; and the anti-HIV1 agent candidate to be examined.Immunovir and components were isolated from Pyrus serotina Rehder and other species of Rosaceae by column chromatography.
-
-
-
-
-
-
-
-
-
搜索结果
400 条记录 (耗时 0.024 秒)
